These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 8765521)

  • 1. Antitumor benzothiazoles. 3. Synthesis of 2-(4-aminophenyl)benzothiazoles and evaluation of their activities against breast cancer cell lines in vitro and in vivo.
    Shi DF; Bradshaw TD; Wrigley S; McCall CJ; Lelieveld P; Fichtner I; Stevens MF
    J Med Chem; 1996 Aug; 39(17):3375-84. PubMed ID: 8765521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor benzothiazoles. 26.(1) 2-(3,4-dimethoxyphenyl)-5-fluorobenzothiazole (GW 610, NSC 721648), a simple fluorinated 2-arylbenzothiazole, shows potent and selective inhibitory activity against lung, colon, and breast cancer cell lines.
    Mortimer CG; Wells G; Crochard JP; Stone EL; Bradshaw TD; Stevens MF; Westwell AD
    J Med Chem; 2006 Jan; 49(1):179-85. PubMed ID: 16392802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and biological properties of benzothiazole, benzoxazole, and chromen-4-one analogues of the potent antitumor agent 2-(3,4-dimethoxyphenyl)-5-fluorobenzothiazole (PMX 610, NSC 721648).
    Aiello S; Wells G; Stone EL; Kadri H; Bazzi R; Bell DR; Stevens MF; Matthews CS; Bradshaw TD; Westwell AD
    J Med Chem; 2008 Aug; 51(16):5135-9. PubMed ID: 18666770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor benzothiazoles. 7. Synthesis of 2-(4-acylaminophenyl)benzothiazoles and investigations into the role of acetylation in the antitumor activities of the parent amines.
    Chua MS; Shi DF; Wrigley S; Bradshaw TD; Hutchinson I; Shaw PN; Barrett DA; Stanley LA; Stevens MF
    J Med Chem; 1999 Feb; 42(3):381-92. PubMed ID: 9986708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of Re and (99m)Tc complexes of 2-(4'-aminophenyl)benzothiazole as potential breast cancer radiopharmaceuticals.
    Tzanopoulou S; Sagnou M; Paravatou-Petsotas M; Gourni E; Loudos G; Xanthopoulos S; Lafkas D; Kiaris H; Varvarigou A; Pirmettis IC; Papadopoulos M; Pelecanou M
    J Med Chem; 2010 Jun; 53(12):4633-41. PubMed ID: 20518489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor activity of imidazothioxanthones in murine and human tumor models in vitro and in vivo.
    Varvaresou A; Iakovou K; Gikas E; Fichtner I; Fiebig HH; Kelland LR; Double JA; Bibby MC; Hendriks HR
    Anticancer Res; 2004; 24(2B):907-19. PubMed ID: 15161044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis, anti-breast cancer activity, and molecular modeling of some benzothiazole and benzoxazole derivatives.
    Abdelgawad MA; Belal A; Omar HA; Hegazy L; Rateb ME
    Arch Pharm (Weinheim); 2013 Jul; 346(7):534-41. PubMed ID: 23740859
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hybrid pharmacophore design and synthesis of isatin-benzothiazole analogs for their anti-breast cancer activity.
    Solomon VR; Hu C; Lee H
    Bioorg Med Chem; 2009 Nov; 17(21):7585-92. PubMed ID: 19804979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor agents. 194. Synthesis and biological evaluations of 4-beta-mono-, -di-, and -trisubstituted aniline-4'-O-demethyl-podophyllotoxin and related compounds with improved pharmacological profiles.
    Zhu XK; Guan J; Tachibana Y; Bastow KF; Cho SJ; Cheng HH; Cheng YC; Gurwith M; Lee KH
    J Med Chem; 1999 Jul; 42(13):2441-6. PubMed ID: 10395485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 2-Substituted aminopyrido[2,3-d]pyrimidin-7(8H)-ones. structure-activity relationships against selected tyrosine kinases and in vitro and in vivo anticancer activity.
    Klutchko SR; Hamby JM; Boschelli DH; Wu Z; Kraker AJ; Amar AM; Hartl BG; Shen C; Klohs WD; Steinkampf RW; Driscoll DL; Nelson JM; Elliott WL; Roberts BJ; Stoner CL; Vincent PW; Dykes DJ; Panek RL; Lu GH; Major TC; Dahring TK; Hallak H; Bradford LA; Showalter HD; Doherty AM
    J Med Chem; 1998 Aug; 41(17):3276-92. PubMed ID: 9703473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and synthesis of potent antitumor 5,4'-diaminoflavone derivatives based on metabolic considerations.
    Akama T; Ishida H; Shida Y; Kimura U; Gomi K; Saito H; Fuse E; Kobayashi S; Yoda N; Kasai M
    J Med Chem; 1997 Jun; 40(12):1894-900. PubMed ID: 9191967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 2-(4-Aminophenyl)benzothiazoles: novel agents with selective profiles of in vitro anti-tumour activity.
    Bradshaw TD; Wrigley S; Shi DF; Schultz RJ; Paull KD; Stevens MF
    Br J Cancer; 1998 Mar; 77(5):745-52. PubMed ID: 9514053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms of acquired resistance to 2-(4-aminophenyl)benzothiazole (CJM 126, NSC 34445).
    Bradshaw TD; Chua MS; Orr S; Matthews CS; Stevens MF
    Br J Cancer; 2000 Jul; 83(2):270-7. PubMed ID: 10901382
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure-activity of novel rhodacyanine dyes as antitumor agents.
    Kawakami M; Koya K; Ukai T; Tatsuta N; Ikegawa A; Ogawa K; Shishido T; Chen LB
    J Med Chem; 1998 Jan; 41(1):130-42. PubMed ID: 9438030
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and anticancer evaluation of bis(benzimidazoles), bis(benzoxazoles), and benzothiazoles.
    Huang ST; Hsei IJ; Chen C
    Bioorg Med Chem; 2006 Sep; 14(17):6106-19. PubMed ID: 16714116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor efficiency of novel fluoro-substituted 6-amino-2-phenylbenzothiazole hydrochloride salts in vitro and in vivo.
    Stojkovic R; Karminski-Zamola G; Racane L; Tralic-Kulenovic V; Glavas-Obrovac L; Ivankovic S; Radacic M
    Methods Find Exp Clin Pharmacol; 2006; 28(6):347-54. PubMed ID: 16894403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 3-methyl-2-(4-substituted phenyl)-4,5-dihydronaphtho[1,2-c]-pyrazoles: synthesis and in-vitro biological evaluation as antitumour agents.
    Al-Saadi MS; Rostom SA; Faidallah HM
    Arch Pharm (Weinheim); 2008 Mar; 341(3):181-90. PubMed ID: 18214843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
    Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
    Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tyrosine kinase inhibitors. 14. Structure-activity relationships for methylamino-substituted derivatives of 4-[(3-bromophenyl)amino]-6-(methylamino)-pyrido[3,4-d]pyrimidine (PD 158780), a potent and specific inhibitor of the tyrosine kinase activity of receptors for the EGF family of growth factors.
    Rewcastle GW; Murray DK; Elliott WL; Fry DW; Howard CT; Nelson JM; Roberts BJ; Vincent PW; Showalter HD; Winters RT; Denny WA
    J Med Chem; 1998 Feb; 41(5):742-51. PubMed ID: 9513602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The discovery of the potent and selective antitumour agent 2-(4-amino-3-methylphenyl)benzothiazole (DF 203) and related compounds.
    Bradshaw TD; Stevens MF; Westwell AD
    Curr Med Chem; 2001 Feb; 8(2):203-10. PubMed ID: 11172675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.